CN102924466A - 一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 - Google Patents
一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 Download PDFInfo
- Publication number
- CN102924466A CN102924466A CN2012104947020A CN201210494702A CN102924466A CN 102924466 A CN102924466 A CN 102924466A CN 2012104947020 A CN2012104947020 A CN 2012104947020A CN 201210494702 A CN201210494702 A CN 201210494702A CN 102924466 A CN102924466 A CN 102924466A
- Authority
- CN
- China
- Prior art keywords
- ketal
- tms
- cdcl
- preparation
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
技术领域
本发明涉及一种简便合成双环缩酮的新方法。
背景技术
[3.3.1]-双环缩酮在科研实验研究过程中的作用巨大,且广泛存在于天然化合物的骨架中,尤其在有机天然产物的合成研究过程中,起到重要的作用,因而受到了广泛的关注。
这里,我们发明了第一例以苯乙酮衍生物与水杨醛衍生物反应的Aldol缩合产物,利用Pd(PhCN)2Cl2、手性配体以及AgBF4作为催化剂甲苯作为溶剂的条件下发生反应,一步便可得目标化合物。构建双环缩酮的方法。该方法的一个显著的特点是反应简单,条件温和,产率较高,具有很高的原子经济性。据我们所知,通过一步合成方法来来构建双环缩酮的方法还未见报道。
发明内容
本发明涉及一种简便的合成[3.3.1]-双环缩酮的新方法。所述的化合物是:将苯乙酮衍生物与水杨醛衍生物在碱性条件下发生Aldol缩合反应,所得的产物在Pd(PhCN)2Cl2、手性配体以及AgBF4作为催化剂甲苯作为溶剂的条件下,加入1.5当量的苯基硼酸,氩气环境下,反应24h,后经浓缩及柱层析得目标化合物。该方法反应简单,产率高,可快速合成各种取代的苯并吡喃环化合物。
在本发明一个优选的技术方案中,R可为羟基、氢、烷基、烷氧基基以及卤素等,R1可为烷基、烷氧基、卤素等。
具体实施方式
其合成路线如下所示:
具体合成步骤如下:将苯乙酮衍生物与水杨醛衍生物在碱性条件下发生Aldol缩合反应,所得的产物在Pd(PhCN)2Cl2、手性配体以及AgBF4作为催化剂甲苯作为溶剂的条件下,加入1.5当量的苯基硼酸,氩气环境下,反应24h,后经浓缩及柱层析得目标化合物。
本发明所合成的双环缩酮化合物,典型地包括下列结构式的化合物,但并不局限于此。
下面通过实施例对本发明作进一步阐述,其目的仅在于更好理解本发明的内容。因此,所举之例并不限制本发明的保护范围。
除有特别说明以外,实施例中所说的薄层层析(TLC)采用山东黄海化学试剂公司生产的型号为HSGF254的硅胶板;柱层析采用山东黄海化学试剂公司生 产的300~400目的硅胶。
实施例1
A将苯乙酮与水杨醛在碱性条件下发生Aldol缩合反应,所得的产物在Pd(PhCN)2Cl2、配体以及AgBF4作为催化剂甲苯作为溶剂的条件下,加入1.5当量的苯基硼酸,氩气环境下,反应24h,后经浓缩及柱层析得目标化合物,收率为75%。
1H NMR(400MHz,CDCl3,TMS):δ2.36(d,J=2.8Hz,2H),4.06(t,J=2.8Hz,1H),6.90(t,J=7.6Hz,2H),7.01(d,J=7.6Hz,2H),7.12(dt,J=1.2,8.0Hz,2H),7.23(dd,J=1.2,7.2Hz,2H),7.37-7.45(m,3H),7.74(dd,J=1.6,8.4Hz,2H); 13C NMR(100MHz,CDCl3,TMS):33.2,34.2,98.6,116.8,121.4,125.8,126.4,127.2,128.0,128.3,128.8,141.4,151.9.
实施例2,其具体合成步骤参考实施例1。
B收率为85%。
1H NMR(400MHz,CDCl3,TMS):δ2.34-2.43(m,2H),3.85(s,3H),4.09(t,J=2.8Hz,1H),6.76(dd,J=2.8,6.8Hz,1H),6.84-6.93(m,3H),7.01(dt,J=1.2,8.4Hz,1H),7.11-7.16(m,1H),7.24-7.26(m,1H),7.38-7.47(m,3H),7.77-7.80(m,2H); 13C NMR(100MHz,CDCl3,TMS):33.2,34.2,56.0,99.6,110.6,116.8,119.0,121.2,121.3,125.9,126.2,127.3,127.4,128.0,128.3,128.7,141.4,152.0.
实施例3,其具体合成步骤参考实施例1。
C收率为93%。
1H NMR(400MHz,CDCl3,TMS):δ2.34-2.42(m,2H),3.74(s,3H),4.04(t,J=3.2Hz,1H),6.50(dd,J=2.4,8.0Hz,1H),6.60(d,J=2.4Hz,1H),6.91(dt,J=1.2,7.6Hz,1H),7.02(d,J=7.6Hz,1H),7.12-7.16(m,2H),7.23(dd,J=3.2,4.6Hz,1H),7.39-7.48(m,3H),7.23(dd,J=1.6,7.6Hz,2H);13C NMR(100MHz,CDCl3,TMS):29.7,33.6,55.4,98.7,101.8,108.2,116.7,118.7,121.5,125.7,126.9,127.0,127.7,127.9,128.3,128.8,141.4,151.8,152.7,159.6.
实施例4,其具体合成步骤参考实施例1。
D收率为95%。
1H NMR(400MHz,CDCl3,TMS):δ2.35-2.37(m,2H),3.76(s,3H),4.03(t;J=3.2Hz,1H),6.70(dd,J=3.2,8.8Hz,1H),6.80(d,J=2.8Hz,1H),6.91(dt,J= 1.6,7.6Hz,1H),6.95(d,J=8.8Hz,1H),7.02(d,J=8.0Hz,1H),7.12-7.16(m,1H),7.24-7.26(m,1H),7.40-7.47(m,3H),7.73-7.76(m,2H);13C NMR(100MHz,CDCl3,TMS):33.2,34.5,55.7,98.6,112.3,113.3,116.7,117.3,121.4,125.7,126.2,126.9,127.2,128.1,128.3,128.7,141.5,145.8,152.1,154.0.
实施例5,其具体合成步骤参考实施例1。
E(式中,X分别为:F、Cl、Br),收率分别为73%、80%和78%。
F:1H NMR(400MHz,CDCl3,TMS):δ2.36-2.40(m,2H),4.06(t,J=2.8Hz,1H),6.84(dt,J=3.2,8.4Hz,1H),6.92-6.98(m,3H),7.04(d,J=8.0Hz,1H),7.77(dt,J=1.6,8.0Hz,1H),7.24-7.26(m,1H),7.42-7.48(m,3H),7.73-7.75(m,2H); 13C NMR(100MHz,CDCl3,TMS):32.9,34.3,98.7,113.3,113.5,114.5,114.7,116.8,117.7,117.8,121.6,125.7,125.8,127.2,127.3,128.2,128.3,128.4,128.9,141.1,147.89,147.91,152.0;19F NMR(470MHz,CDCl3,TMS)δ-122.6.
Cl:1H NMR(400MHz,CDCl3,TMS):δ2.34-2.42(m,2H),4.06(t,J=2.8Hz,1H),6.92-6.96(m,2H),7.03(d,J=8.0Hz,1H),7.09(dd,J=2.4,8.4Hz,1H),7.15-7.19(m,1H),7.23-7.26(m,2H),7.42-7.48(m,3H),7.72-7.74(m,2H);13CNMR(100MHz,CDCl3,TMS):32.9,34.1,98.8,116.9,118.1,121.7,125.6,125.7,126.0,126.9,127.3,127.8,127.9,128.4,128.9,140.9,150.6,151.8.
Br:1H NMR(400MHz,CDCl3,TMS):δ2.34-2.42(m,2H),4.06(t,J=3.2Hz,1H),6.90(d,J=8.8Hz,1H),6.95(dt,J=0.8,7.2Hz,1H),7.03(d,J=7.6Hz,1H),7.17(dt,J=1.2,7.6Hz,1H),7.22-7.26(m,2H),7.38(d,J=2.4Hz,1H),7.42-7.48(m,3H),7.71-7.74(m,2H);13C NMR(100.MHz,CDCl3,TMS):32.8,34.0,98.7,113.4,116.9,118.6,121.7,125.6,125.7,127.3,128.38,128.41,128.9,129.8,130.9,140.9,151.2,151.8.
实施例6,其具体合成步骤参考实施例1。
F,收率为63%。
1H NMR(400MHz,CDCl3,TMS):δ2.27(s,3H),2.37(d,J=3.2Hz,2H),4.04(t,J=3.2Hz,1H),6.90-6.94(m,3H),7.02(d,J=8.4Hz,1H),7.06(s,1H),7.14(dt,J=1.6,7.6Hz,1H),7.26(dt,J=1.6,7.6Hz,1H),7.40-7.47(m,3H),7.73-7.76(m,2H);13C NMR(100MHz,CDCl3,TMS):20.5,33.3,34.2,98.6,116.5,116.7,121.4,125.8,126.0,126.5,127.2,127.6,128.0,128.3,128.6,128.7,130.7, 141.5,149.7,152.0.
实施例7,其具体合成步骤参考实施例1。
G(结构中,OH分别在3-位、4-位和5-位),收率分别为85%、89%和93%。
3-位:1H NMR(400MHz,CDCl3,TMS):δ2.36-2.38(m,2H),4.01(t,J=2.4Hz,1H),4.58(s,1H),6.61(dd,J=2.8,8.4Hz,1H),6.75(d,J=3.2Hz,1H),6.90(d,J=8.4Hz,1H),6.92(dt,J=0.8,7.6Hz,1H),7.03(d,J=7.6Hz,1H),7.13-7.19(m,1H),7.22-7.25(m,1H),7.41-7.48(m,5H),7.73-7.76(m,2H);13C NMR(100MHz,CDCl3,TMS):33.2,34.3,98.6,113.5,114.9,116.7,117.5,121.4,125.7,126.1,127.1,127.2,128.1,128.2,128.3,128.7,129.0,141.4,145.8,149.7,152.1.
4-位:1H NMR(400MHz,CDCl3,TMS):δ2.35-2.37(m,2H),4.01(t,J=2.4Hz,1H),4.62(s,1H),6.61(dd,J=2.8,8.4Hz,1H),6.75(d,J=3.2Hz,1H),6.90(d,J=8.4Hz,1H),6.92(dt,J=0.8,7.6Hz,1H),7.03(d,J=7.6Hz,1H),7.13-7.19(m,1H),7.22-7.25(m,1H),7.41-7.48(m,3H),7.73-7.76(m,2H);13C NMR(100MHz,CDCl3,TMS):33.2,34.3,98.6,113.5,114.9,116.7,117.4,121.5,125.6,126.1,127.1,127.2,128.1,128.2,128.3,128.7,129.0,141.4,145.8,149.7,152.1.
5-位:1H NMR(400MHz,CDCl3,TMS):δ2.36-2.38(m,2H),4.01(t,J=2.4Hz,1H),4.67(s,1H),6.61(dd,J=2.8,8.4Hz,1H),6.75(d,J=3.2Hz,1H),6.90(d,J=8.4Hz,1H),6.92(dt,J=0.8,7.6Hz,1H),7.03(d,J=7.6Hz,1H),7.13-7.19(m,1H),7.22-7.25(m,1H),7.41-7.48(m,3H),7.73-7.76(m,2H);13C NMR(100MHz,CDCl3,TMS):33.2,34.3,98.6,113.5,114.9,116.7,117.5,121.4,125.7,126.1,127.1,127.2,128.0,128.2,128.3,128.7,129.0,141.4,145.9,149.7,153.1.
实施例8,其具体合成步骤参考实施例1。
H收率为78%。
1H NMR(400MHz,CDCl3,TMS):δ2.41-2.53(m,2H),4.23(t,J=2.8Hz,1H),6.99(dt,J=1.2,7.2Hz,1H),7.06(d,J=8.0Hz,1H),7.00(d,J=9.2Hz,1H),7.19-7.23(m,1H),7.32(dd,J=2.0,7.6Hz,1H),7.46-7.52(m,3H),7.72-7.75(m,2H),8.07(dd,J=2.8,9.2Hz,1H),8.21(d,J=2.4Hz,1H);13C NMR(100MHz,CDCl3,TMS):32.5,33.9,99.4,117.1,117.4,122.2,123.4,124.2,124.8,125.6,127.3,127.4,128.5,128.8,129.3,140.1,141.8,151.3,157.6.
实施例9,其具体合成步骤参考实施例1。
I(结构式中,X1分别为Cl、Br和甲基),收率分别为45%、41%和84%。
Cl:1H NMR(400MHz,CDCl3,TMS):δ2.54(dd,J=3.2,9.6Hz,1H),2.70(dd,J=3.2,9.6Hz,1H),3.86(s,3H),4.10(t,J=2.4Hz,1H),6.75-6.79(m,1H),6.85-6.94(m,3H),7.00(d,J=8.0Hz,1H),7.13-7.17(m,1H),7.25-7.27(m,1H),7.33-7.40(m,2H),7.44(dd,J=1.2,7.6Hz,1H),8.19(dd,J=2.0,7.6Hz,1H);13CNMR(100MHz,CDCl3,TMS):31.6,33.7,53.4,98.3,110.6,117.0,118.9,121.3,121.4,126.2,126.8,127.2,127.4,128.0,129.0,130.0,131.5,132.7,137.6,140.9,148.5,151.6.
Br:1H NMR(400MHz,CDCl3,TMS):δ2.55(dd,J=3.2,9.2Hz,1H),2.74(dd,J=3.2,9.2Hz,1H),3.86(s,3H),4.10(t,J=1.2Hz,1H),6.75-6.79(m,1H),6.87-6.94(m,3H),7.00(d,J=7.6Hz,1H),7.13-7.17(m,1H),7.22-7.26(m,2H),7.43(dt,J=1.6,8.0Hz,1H),7.67(dd,J=1.2,8.0Hz,1H),8.21(dd,J=2.0,7.6Hz,1H);13C NMR(100MHz,CDCl3,TMS):29.0,33.6,53.4,98.7,110.6,117.1,118.9,121.3,121.4,126.2,127.2,127.38,127.43,128.0,129.3,130.2,135.1,139.0,140.9,148.5,151.6.
甲基:1HNMR(400MHz,CDCl3,TMS):δ2.45-2.46(m,2H),2.51(s,3H),3.83(s,3H),4.10(t,J=2.8Hz,1H),6.75(dt,J=2.8,7.2Hz,1H),6.84-6.92(m,3H),6.99(d,J=8.0Hz,1H),7.12-7.16(m,1H),7.23-7.30(m,4H),7.89-7.91(m,1H); 13C NMR(100MHz,CDCl3,TMS):21.3,30.6,33.9,53.4,99.5,110.5,116.9,118.9,121.2,121.3,125.9,126.3,126.8,127.3,127.5,128.0,128.8,132.4,136.5,138.8,140.9,148.5,151.6.
实施例10,其具体合成步骤参考实施例1。
J(结构中X2为Cl),收率为73%。
1H NMR(400MHz,CDCl3,TMS):δ2.31-2.39(m,2H),3.84(s,3H),4.09(t,J=2.8Hz,1H),6.73-6.77(m,1H),6.86-6.88(m,2H),6.91(dt,J=1.2,7.6Hz,1H),7.01(d,J=7.2Hz,1H),7.12-7.16(m,1H),7.24(dd,J=1.2,7.2Hz,1H),7.37-7.38(m,2H),7.65-7.68(m,1H),7.77-7.78(m,1H);13C NMR(100MHz,CDCl3,TMS):33.1,34.0,58.4,98.1,110.5,116.8,118.9,121.4,121.6,124.2,126.0,126.4,127.2,127.3,128.1,128.8,129.7,134.2,141.1,143.4,148.3,151.7.
实施例11,其具体合成步骤参考实施例1。
K(结构中M为F、Cl、甲基、对三氟甲基和甲氧基)收率分别为66%、98%、97%、20%和95%。
F:1H NMR(400MHz,CDCl3,TMS):δ2.31-2.40(m,2H),3.83(s,3H),4.09(t,J=2.8Hz,1H),6.74-6.76(m,1H),6.86-6.93(m,3H),6.99(d,J=7.2Hz,1H),7.09-7.15(m,3H),7.23-7.26(m,1H),7.74-7.78(m,2H);13C NMR(100MHz,CDCl3,TMS):33.3,34.1,55.9,98.3,110.5,115.0,115.2,116.8,118.9,121.3,121.5,126.0,127.25,127.29,127.9,127.99,128.03,137.39,137.42,141.2,148.3,151.8,161.7,164.2.19F NMR(470MHz,CDCl3,TMS)δ-113.7.
Cl:1H NMR(400MHz,CDCl3,TMS):δ2.30-2.39(m,2H),3.83(s,3H),4.09(t,J=2.8Hz,1H),6.73-6.77(m,1H),6.86-6.93(m,3H),6.99(d,J=7.6Hz,1H),7.13(dt,J=1.2,7.2Hz,1H),7.24(dd,J=1.6,7.6Hz,1H),7.39-7.43(m,2H),7.70-7.74(m,2H);13C NMR(100MHz,CDCl3,TMS):33.1,34.0,55.9,98.2,110.5,116.8,118.9,121.4,121.5,126.0,127.2,127.3,127.5,128.0,128.5,134.6,140.0,141.1,148.3,151.8.
甲基: 1H NMR(400MHz,CDCl3,TMS):δ2.34-2.42(m,5H),3.84(s,3H),4.08(t,J=2.8Hz,1H),6.75(dd,J=2.8,6.8Hz,1H),6.83-6.92(m,3H),7.00(d,J=7.6Hz,1H),7.10-7.15(m,1H),7.23-7.26(m,2H),7.67(d,J=8.4Hz,1H),7.92(d,J=8.0Hz,2H);13C NMR(100MHz,CDCl3,TMS):21.2,33.2,34.2,56.0,98.6,110.6,116.8,119.0,121.1,121.3,125.8,126.2,127.2,127.4,127.9,128.9,138.4,138.6,141.5,148.4,152.1.
对三氟甲基:1H NMR(400MHz,CDCl3,TMS):δ2.33-2.42(m,2H),3.85(s,3H),4.12(t,J=2.8Hz,1H),6.75-6.79(m,1H),6.89-6.90(m,2H),6.93(dt,J=0.8,7.2Hz,1H),.7.02(d,J=8.0Hz,1H),7.15(dt,J=1.6,7.6Hz,1H),7.25-7.28(m,1H),7.71.(d,J=7.6Hz,2H),7.92(d,J=8.0Hz,2H);13C NMR(100MHz,CDCl3,TMS):33.0,34.0,56.0,98.2,110.6,116.8,118.9,121.5,121.7,125.34,125.38,125.43,125.9,126.6,127.2,127.4,128.1,130.7,131.0,141.0,145.2,148.4,151.7. 19F NMR(470MHz,CDCl3,TMS)δ-62.6.
甲氧基:1H NMR(400MHz,CDCl3,TMS):δ2.32-2.41(m,2H),3.830(s,3H),3.833(s,3H),4.07(t,J=3.2Hz,1H),6.73-6.75(m,1H),6.83-6.91(m,3H), 6.94-7.00(m,3H),7.10-7.14(m,1H),7.23-7.25(m,1H),7.69-7.72(m,2H);13CNMR(100MHz,CDCl3,TMS):33.2,34.3,55.3,56.0,98.5,110.5,113.5,116.8,118.9,121.1,121.3,126.2,127.2,127.4,127.9,133.8,141.5,148.4,152.1,159.8.
实施例12,其具体合成步骤参考实施例1。
L(R为烷基,如:甲基、乙基、异丙基和正己基)甲基收率:90%,乙基收率:93%,异丙基收率:43%,正己基收率:85%。
甲基:1H NMR(400MHz,CDCl3,TMS):δ1.93(s,3H),2.19-2.28(m,2H),3.81(s,3H),3.99(t,J=2.8Hz,1H),6.66-6.70(m,1H),6.77-6.85(m,4H),7.06(dt,J=1.2,8.0Hz,1H),7.17(dd,J=1.2,8.0Hz,1H);13C NMR(100MHz,CDCl3,TMS):27.4,30.9,33.8,55.9,97.8,110.1,116.4,119.1,120.87,120.93,126.3,127.0,127.1,127.8,141.1,147.9,151.8.
乙基:1H NMR(400MHz,CDCl3,TMS):δ1.15(t,J=7.2Hz,3H),2.18-2.26(m,4H),3.82(s,3H),4.01(t,J=2.8Hz,1H),6.69(dd,J=2.4,7.2Hz,1H),6.78-6.87(m,4H),7.05-7.09(m,1H),7.17(dd,J=1.6,7.6Hz,1H);13C NMR(100MHz,CDCl3,TMS):8.0,28.3,33.0,33.6,56.0,99.8,110.3,116.5,119.1,120.8,120.9,126.5,127.0,127.4,127.8,141.4,148.0,152.1.
异丙基:1H NMR(400MHz,CDCl3,TMS):δ1.16(d,J=5.6Hz,3H),1.19(d,J=5.6Hz,3H),2.10-2.18(m,2H),2.44-2.51(m,1H),3.81(s,3H),4.00(t,J=2.8Hz,1H),6.69(dd,J=2.0,7.2Hz,1H),6.77-6.88(m,4H),7.07(dd,J=1.2,8.0Hz,1H),7.18(dd,J=1.6,7.6Hz,1H);13C NMR(100MHz,CDCl3,TMS):16.8,17.1,25.6,33.4,36.9,56.1,101.5,110.6,116.5,119.0,120.6,120.8,126.6,127.1,127.6,127.8,141.7,148.2,152.2.
正己基:1H NMR(400MHz,CDCl3,TMS):δ0.90(t,J=7.2Hz,3H),1.26-1.43(m,6H),1.55-1.61(m,2H),2.13-2.24(m,4H),3.80(s,3H),3.99(t,J=2.8Hz,1H),6.68(dd,J=2.8,6.8Hz,1H),6.77-6.86(m,4H),7.04-7.08(m,1H),7.17(dd,J=1.2,7.2Hz,1H);13C NMR(100MHz,CDCl3,TMS):14.1,22.6,23.4,28.8,29.3,31.7,33.6,40.0,55.9,99.5,110.3,116.4,119.1,120.7,120.8,126.5,127.0,127.4,127.7,141.3,148.0,152.0.
实施例13,其具体合成步骤参考实施例1。
M收率为64%。
1H NMR(400MHz,CDCl3,TMS):δ2.54(t,J=2.8Hz,2H),3.84(s,3H),4.11(t,J=2.8Hz,1H),6.73-6.77(m,1H),6.86-6.88(m,2H),6.91(dt,J=1.2,7.2Hz,1H),6.99(d,J=8.0Hz,1H),7.06(dd,J=3.6,5.2Hz,1H),7.11-7.15(m,1H),7.24(dd,J=1.2,7.6Hz,1H),7.35-7.37(m,2H);13C NMR(100MHz,CDCl3,TMS):33.4,34.2,56.1,97.6,110.8,116.9,119.0,121.5,121.6,125.2,125.9,126.0,126.8,127.1,127.2,128.0,141.1,144.9,148.3,151.6。
Claims (6)
2.如权利要求1所述此类结构化合物,其特征在于,R可以为羟基或者氢等官能团,R2为烷基、烷氧基、卤素等;此外,与氧相连的季碳原子可不与苯基相连,直接与烷基相连,反应兼容性强。
3.如权利1~2要求的双环缩酮化合物,其特征在于,在制备过程中并没有采用了严格苛刻的反应条件催化剂,使制备方法非常廉价简单,且操作容易并达到了95%以上的原子经济性。
5.如权利4要求的双环缩酮的制备方法,其特征在于,在制备过程中采用了较为温和的制备方法和较为廉价的原料。
6.如权利要求4所述的制备方法,其特征在于,所述的制备方法包括如下步骤:将苯乙酮衍生物与水杨醛衍生物在碱性条件下发生Aldol缩合反应,所得的产物在Pd(PhCN)2Cl2、 手性配体以及AgBF4作为催化剂甲苯作为溶剂的条件下,加入1.5当量的苯基硼酸,氩气环境下,反应24h,后经浓缩及柱层析得目标化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012104947020A CN102924466A (zh) | 2012-11-28 | 2012-11-28 | 一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012104947020A CN102924466A (zh) | 2012-11-28 | 2012-11-28 | 一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102924466A true CN102924466A (zh) | 2013-02-13 |
Family
ID=47639420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012104947020A Pending CN102924466A (zh) | 2012-11-28 | 2012-11-28 | 一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102924466A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210785A1 (en) * | 1985-07-19 | 1987-02-04 | IDB HOLDING S.p.A. | Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use |
CN1273985A (zh) * | 1999-05-17 | 2000-11-22 | 中国科学院华南植物研究所 | 原花色素的制备工艺 |
CN1431205A (zh) * | 2002-01-11 | 2003-07-23 | 华中农业大学 | 一种用于从植物中提取原花青素的萃取剂及提取方法 |
-
2012
- 2012-11-28 CN CN2012104947020A patent/CN102924466A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0210785A1 (en) * | 1985-07-19 | 1987-02-04 | IDB HOLDING S.p.A. | Process for obtaining proanthocyanidine A2, pharmaceutical compositions and their therapeutic use |
CN1273985A (zh) * | 1999-05-17 | 2000-11-22 | 中国科学院华南植物研究所 | 原花色素的制备工艺 |
CN1431205A (zh) * | 2002-01-11 | 2003-07-23 | 华中农业大学 | 一种用于从植物中提取原花青素的萃取剂及提取方法 |
Non-Patent Citations (2)
Title |
---|
POMILIO, ALICIA 等: "The proanthocyanidins, XXII. The constitution of condensation products of phenols with flavylium salts", 《JUSTUS LIEBIGS ANN. CHEM》, 31 December 1977 (1977-12-31), pages 597 - 601 * |
ROSANA M. LOBAYAN ET AL: "Conforma tional and electronic (AIM/NBO) study of unsubs tituted A-t ype dimeric proantho cyanidin", 《J MOL MODEL》, 31 December 2009 (2009-12-31), pages 537 - 538 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gui et al. | A cinchona alkaloid catalyzed enantioselective sulfa-Michael/aldol cascade reaction of isoindigos: construction of chiral bispirooxindole tetrahydrothiophenes with vicinal quaternary spirocenters | |
CN108314658B (zh) | 一种多取代噁唑衍生物的制备方法 | |
CN105906537B (zh) | (z)式磺酰基烯酸酯化合物的一锅合成方法 | |
CN108911937B (zh) | 四芳基乙烯类化合物的合成方法 | |
CN108912076B (zh) | 一种苯并氧杂环化合物的合成方法 | |
CN105820174A (zh) | 一种多取代噻吩并吲哚衍生物的制备方法 | |
CN102924466A (zh) | 一种简便的合成[3.3.1]-双环缩酮及其衍生物的新方法 | |
CN110698426B (zh) | 叔丁醇钾高效催化制备1,3-苯并噻唑衍生物的方法 | |
CN108727323B (zh) | 一种氮杂环卡宾催化合成三氟甲基取代高异黄酮类化合物的方法 | |
CN110467527B (zh) | 一种制备反式右旋菊酸的方法 | |
CN112851652A (zh) | 一种2-(取代氧杂蒽基)苯并呋喃类化合物的催化氧化合成方法 | |
Yang et al. | Condensation‐ring Expansion Reaction of Formyl [2.2. 1] bicyclic Carbinols with Para‐substituted Phenyl Amines: Application to the Preparation of [3.2. 1] bicyclic N‐aryl‐1, 2, 3‐oxathiazolidine‐2‐oxide Agents | |
KR101686087B1 (ko) | 광학 활성을 갖는 인돌린 유도체 또는 이의 염의 신규 제조 방법 | |
CN111100085A (zh) | 一种3-芳基-2H-苯并[β][1,4]苯并恶嗪-2-酮化合物的制备方法 | |
JP5232989B2 (ja) | 光学活性2,6−ビスアミノメチルピリジン誘導体とその製造方法およびその使用 | |
CN113234083B (zh) | 四氢喹啉并吡喃类化合物及其制备方法和应用 | |
CN108546244B (zh) | 一种3,3’-二吲哚乙烷类化合物的合成方法 | |
KR101554539B1 (ko) | 금속이 배제된 호기성 산화 아민화 반응을 이용한 아마이드 화합물의 제조방법 | |
CN108101758B (zh) | 一种制备手性炔丙基化的脂肪族六元碳环类化合物的方法 | |
CN113004235B (zh) | 一种(z)-3-烯基苯酞衍生物的立体选择性合成方法 | |
CN115819208B (zh) | 一种2-芳基-3,4-二氢-1(2h)-萘酮类化合物的合成方法 | |
KR20110039826A (ko) | 키랄 촉매를 이용한 키랄 베타-플루오로알킬화 카보닐 화합물의 제조방법 | |
CN108912000B (zh) | 二苯基四氢化双吲哚衍生物催化不对称Mannich反应的应用 | |
CN108558751B (zh) | 3-硝基喹啉衍生物的合成工艺 | |
KR101087500B1 (ko) | 바이나프톨 알데히드 유도체 및 그의 중간체의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130213 |